Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD)

Next Previous
Search
Trial Profile

A Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Neflamapimod (Primary)
  • Indications Huntington's disease
  • Focus Proof of concept; Therapeutic Use
  • Sponsors EIP Pharma

    • Most Recent Events

    • 10 Aug 2021 Status changed from recruiting to discontinued due to the long delay because of COVID-19 and results from another study suggesting a higher dose may be more beneficial.
    • 16 Dec 2020 This trial has been discontinued in United Kingdom (Date of the global end of the trial: 15 Oct 2020).
    • 09 Jul 2019 Status changed from not yet recruiting to recruiting, according to an EIP Pharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top